Top

Published in:

01-10-2015 | What's New in Intensive Care

What’s new about heparin-induced thrombocytopenia type II

Author: Yasser Sakr

Published in: Intensive Care Medicine | Issue 10/2015

Excerpt

Heparin-induced thrombocytopenia type II (HIT) is an immune-mediated, prothrombotic serious adverse event that can occur due to heparin administration. The platelet-activating immune response is triggered by the interaction of heparin with a specific platelet protein, platelet factor 4 (PF4) [1]. Antithrombosis prophylaxis is a cornerstone in the management of critically ill patients and HIT is, therefore, a major concern in intensive care unit (ICU) patients [1]. …

Sakr Y (2011) Heparin-induced thrombocytopenia in the ICU: an overview. Crit Care 15:211PubMedCentralCrossRefPubMed

Aster RH (1995) Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332:1374–1376CrossRefPubMed

Battistelli S, Genovese A, Gori T (2010) Heparin-induced thrombocytopenia in surgical patients. Am J Surg 199:43–51CrossRefPubMed

Zheng Y, Yu M, Padmanabhan A, Aster RH, Yuan L, Wen R, Wang D (2015) Critical role of CD4 T cells in PF4/heparin antibody production in mice. Blood 125:1826–1829

Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM (2015) A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost 113:772–781

Davidson SJ, Wadham P, Rogers L, Burman JF (2007) Endothelial cell damage in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 18:317–320CrossRefPubMed

Bakchoul T, Greinacher A (2012) Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Ther Adv Hematol 3:237–251PubMedCentralCrossRefPubMed

Warkentin TE, Crowther MA (2007) When is HIT really HIT? Ann Thorac Surg 83:21–23CrossRefPubMed

Pohl C, Klockgether T, Greinacher A, Hanfland P, Harbrecht U (1999) Neurological complications in heparin-induced thrombocytopenia. Lancet 353:1678–1679CrossRefPubMed

10.

Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765CrossRefPubMed

11.

Joseph L, Gomes MP, Al SF, St John J, Ozaki A, Raju M, Dhariwal M, Kim ES (2015) External validation of the HIT Expert Probability (HEP) Score. Thromb Haemost 113:633–640

12.

Chan CM, Woods CJ, Warkentin TE, Sheppard JA, Shorr AF (2015) The role for optical density in heparin-induced thrombocytopenia: A cohort study. Chest. doi:10.1378/chest.14-1417

13.

Tan CW, Ward CM, Morel-Kopp MC (2012) Evaluating heparin-induced thrombocytopenia: the old and the new. Semin Thromb Hemost 38:135–143CrossRefPubMed

14.

Schallmoser K, Drexler C, Rohde E, Strunk D, Groselj-Strele A, Lanzer G, Kroll H, Panzer S (2009) The particle gel immunoassay as a rapid test to rule out heparin-induced thrombocytopenia? J Thorac Cardiovasc Surg 137:781–783CrossRefPubMed

15.

Greinacher A, Gopinadhan M, Gunther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA (2006) Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26:2386–2393CrossRefPubMed

16.

Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de ME, Biron C, Huisse MG, Ternisien C, Voisin S, Gruel Y, Pouplard C (2014) Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay [STic Expert(R) HIT] for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 166:774–782CrossRefPubMed

17.

Warkentin TE, Chong BH, Greinacher A (1998) Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1–7PubMed

18.

Selleng K, Warkentin TE, Greinacher A (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35:1165–1176CrossRefPubMed

19.

Watson H, Davidson S, Keeling D (2012) Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 159:528–540PubMed

20.

Prechel M, Walenga JM (2012) Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 38:483–496CrossRefPubMed

21.

McKenzie SE, Sachais BS (2014) Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol 21:380–387PubMedCentralCrossRefPubMed

22.

Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F (2015) New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res 135:607–609

23.

Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G (2010) Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 110:30–35CrossRefPubMed

Title: What’s new about heparin-induced thrombocytopenia type II
Author: Yasser Sakr
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 10/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-015-3811-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

What’s new about heparin-induced thrombocytopenia type II

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2015

Acute ruptured mycotic aneurysm mimicking myocardial tumor with ST elevation myocardial infarction

Ten false beliefs about cortisol in critically ill patients

Effects of propofol on diaphragmatic electrical activity in mechanically ventilated pediatric patients

Should cost considerations be included in medical decisions? Yes

Should cost considerations be included in medical decisions? Not so sure…

Sounding board: is mandatory recovery of organs for transplantation acceptable?